Please login to the form below

Not currently logged in
Email:
Password:

Dr Julian Howell joins Shield Therapeutics as group medical director

Mineral medicines company also appoints Dr Lynn Drummond to the board

Shield Therapeutics medical director Dr Julian HowellUK mineral medicines company Shield Therapeutics has appointed Dr Julian Howell as group medical director and VP of drug development.

He joins the specialty pharma company after spending six years at ProStrakan, where he led its clinical development and drug safety group.

Dr Howell spent six years in the NHS, gaining medical and surgical qualifications, and began his industry career with SmithKline Beecham and then at Roche, before moving to smaller companies.

Dr Howell said: “I am very pleased to be joining the team at Shield … I look forward to adding my clinical development experience and medical knowledge to the skilled team already in place to help ensure that our products become available as quickly and safely as possible to patients with such clear unmet medical needs.”

Shield Therapeutics has also appointed Dr Lynn Drummond to its board as a non-executive director.

She has over 25 years of management and advisory experience, spending 16 years at Rothschild in London, most recently as a managing director within the investment banking division, with a particular focus on transactions within the healthcare sector.

13th May 2013

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
GCI Health

GCI Health is an integrated communications agency designed for and inspired by the ever-changing face of healthcare. In London, we...

Latest intelligence

“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...

Infographics